Transport characteristics of peptidomimetics. Effect of the pyrrolinone bioisostere on transport across Caco-2 cell monolayers

Pharmaceutical Research

Volumn 15, Issue 5, 1998, Pages 719-725

  Sudoh, Masao ^a   Pauletti, Giovanni M ^a,b   Yao, Wenqing ^c,f   Moser, William ^c   Yokoyama, Akihisa ^c,g   Pasternak, Alexander ^c,d   Sprengeler, Paul A ^c,e   Smith III, Amos B ^c   Hirschmann, Ralph ^c   Borchardt, Ronald T ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Arris Pharmaceutical Corporation   (United States)

^f DUPONT COMPANY   (United States)

^g Yamakatsu Bldg   (Japan)

Author keywords

Caco 2 cells; Membrane permeability; Peptidomimetics; Polarized efflux systems; Pyrrolinone bioisostere

Indexed keywords

PEPTIDE DERIVATIVE; PROTEINASE INHIBITOR; PYRROLINE DERIVATIVE;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL MEMBRANE TRANSPORT; CELL STRAIN CACO 2; CHEMICAL BOND; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG STRUCTURE; DRUG UPTAKE; HUMAN; HUMAN CELL; INTESTINE MUCOSA PERMEABILITY; MOLECULAR WEIGHT; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HIV PROTEASE INHIBITORS; HUMANS; MOLECULAR MIMICRY; PEPTIDES;

EID: 15644375810     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011966918959     Document Type: Article

References (32)

1. J. J. Plattner and D. J. Norbeck. Obstacles to drug development from peptide leads. In C. R. Clark and W. H. Moos (eds.), Drug Discovery Technologies, Ellis Horwood, Chichester (UK), 1990, pp. 92-126.
2. G. M. Pauletti, S. Gangwar, G. T. Knipp, M. M. Nerurkar, F. W. Okumu, K. Tamura, T. J. Sinhaan, and R. T. Borchardt. Structural requirements for intestinal absorption of peptide drugs. J. Controlled Release 41:3-17 (1996).
3. G. M. Pauletti, S. Gangwar, T. J. Siahaan, J. Aubé, and R. T. Borchardt. Improvement of oral peptide bioavailability: peptidomimetics and prodrug strategies. Adv. Drug Delivery Rev. 27:235-256 (1997).
4. J. R. Huff. HIV protease - A novel chemotherapeutic target for AIDS. J. Med. Chem. 34:2305-2314 (1991).
5. I. Ojima, S. Chakravarty, and Q. Dong. Antithrombic agents: from RGD to peptide mimetics. Bioorg. Med. Chem. 3:337-360 (1995).
6. J. B. Kostis and E. A. DeFelice. Angiotensin Converting Enzyme Inhibitors, Alan R. Liss, New York, NY, 1987.
7. J. Boger. Renin inhibitors. Annu. Rep. Med. Chem. 20:257-266 (1985).
8. W. J. Greenlee. Renin inhibitors. Med. Res. Rev. 10:173-236 (1990).
9. H. D. Kleinert, S. H. Rosenberg, W. R. Baker, H. H. Stein, V. Klinghofer, J. Barlow, K. Spina, J. Polakowski, P. Kovar, J. Cohen, and J. Denissen. Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. Science 257:1940-1943 (1992).
10. R. J. Simon, R. S. Kania, R. N. Suckermann, V. D. Huebner, D. A. Jewell, S. C. Banville, S. Ng, L. Wang, S. Rosenberg, C. K. Marlowe, D. Spellmeyer, R. Tan, A. D. Frankel, D. Santi, F. E. Cohen, and P. A. Bartlett. Peptoids - A modular approach to drug discovery. Proc. Natl. Acad. Sci. USA 39:9367-9371 (1992).
11. J. J. Nestor Jr. Improved duration of action of peptide drugs. In M. D. Taylor and G. L. Amidon (eds.), Peptide-Based Drug Design: Controlling Transport and Metabolism, American Chemical Society, Washington, DC, 1995, pp. 449-471.
12. T. K. Sawyer. Peptidomimetic design and chemical approaches to petides metabolism. In M. D. Taylor and G. L. Amidon (eds.), Peptide-Based Drug Design, American Chemical Society, Washington, DC, 1995, pp. 387-422.
13. A. B. I. Smith, T. P. Keenan, R. C. Holcomb, P. A. Sprengeler, M. C. Guzman, J. L. Wood, P. J. Carroll, and R. Hirschmann. Design, synthesis, and crystal structure of a pyrrolinone-based peptidomimetic possessing the conformation of a β-strand: Potential application to the design of novel inhibitors of proteolytic enzymes. J. Am. Chem. Soc. 114:10672-10674 (1992).
14. M. Miller, J. Schnieder, B. K. Sathyanarayana, M. V. Toth, G. R. Marshall, L. Clawson, L. M. Selk, S. B. H. Kent, and A. Wlodawer. Structure of complex of sunthetic HIV 1 protease with a substrate-based inhibitor at 2.3Å resolution. Science 246:1149-1152 (1989).
15. A. B. Smith III, R. Hirschmann, A. Pasternack, R. Akaishi, M. C. Guzman, D. R. Jones, T. P. Keenan, and P. A. Sprengeler. Design and synthesis of peptidomimetic inhibitors of HIV-1 protease and renin. Evidence for improved transport. J. Med. Chem. 37:215-218 (1994).
16. P. Artursson. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 79:476-482 (1990).
17. M. Pinto, S. Robine-Leon, M.-D. Appay, M. Kedinger, N. Tradou, E. Dussaulx, B. Lacroix, P. Simon-Assmann, K. Haffen, J. Fogh, and A. Zweibaum. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol. Cell 47:323-330 (1983).
18. G. Wilson, I. F. Hassan, C. J. Dix, I. Williamson, R. Shah, and M. Mackay. Transport and permeability properties of human Caco-2 cells: an in vitro model of the intestinal epithelial cell barrier. J. Contr. Rel. 11:25-40 (1990).
19. J. P. Vacca, B. D. Dorsey, W. A. Schleiff, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Holloway, J. Lin. I.-W. Chen. K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, and J. R. Huff. L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100 (1994).
20. A. B. Smith III, R. Hirschmann, A. Pasternak, M. C. Guzman, and P. A. Sprengeler. Pyrrolinone based HIC protease inhibitors. Design, synthesis and antiviral activity; evidence for improved transport. J. Am. Chem. Soc. 117:11113-11123 (1995).
21. A. B. Smith III, R. Hirschmann, A. Pasternack, W. Yao, P. A. Sprengeler, M. K. Holloway, L. C. Kuo, Z. Chen, P. L. Darke, and W. A. Schleif. An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex. J. Med. Chem. 40:2240-2444 (1997).
22. G. M. Pauletti, S. Gangwar, F. W. Okumu, T. J. Siahaan, V. J. Stella, and R. T. Borchardt. Esterase-sensitive cyclic prodrugs of peptides: evaluation of an acylxoyalkoxy promoiety in a model hexapeptide. Pharm. Res. 13:1615-1623 (1996).
23. H. Liu, S. Ong, L. Glunz, and C. Pidgeon. Predicting drug-membrane interactions by HPLC: structural requirements of chromatographic surfaces. Anal. Chem. 67:3550-3557 (1995).
24. P. S. Burton, R. A. Conradi, and N. F. H. Ho. Evidence for a polarized efflux system for peptides in the apical region of Caco-2 cells. Biochem. Biophys. Res. Commun. 190:760-766 (1993).
25. M. M. Gottesman and I. Pastan. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. 62:385-427 (1993).
26. W. H. M. Peters, C. E. W. Boon, H. M. J. Roelofs, T. Wobbes, F. M. Nagengast, and P. G. Kremers. Expression of drug-metabolizing enzymes and P-170 glycoprotein in colorectal carcinoma and normal mucosa. Gastroenterology 103:448-455 (1992).
27. P. S. Burton, J. T. Goodwin, R. A. Conradi, N. F. H. Ho, and A. R. Hilgers. In vitro Permeability of peptidomimetic drugs: the role of polarized efflux pathways as additional barriers to absorption. Adv. Drug Delivery Rev. 23:143-156 (1997).
28. P. S. Burton, R. A. Conradi, N. F. H. Ho, A. R. Hilgers, and R. T. Borchardt. How structural features influence the bio-membrane permeability of peptides. J. Pharm. Sci. 85:1336-1340 (1996).
29. C. Pidgeon, S. Ong, H. Liu, X. Qiu, M. Pidgeon, A. H. Dantzig, J. Munroe, W. J. Hornback, J. S. Kasher, L. Glunz, and T. Szczerba. IAM Chromatography: an in vitro screen for predicting drug membrane permeability. J. Med. Chem. 38:590-594 (1995).
30. W. T. Klimecki, B. W. Futscher, T. M. Grogan, and W. S. Dalton. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83:2451-2458 (1994).
31. A. Andreana, S. Aggarwal, S. Gollapudi, D. Wien, T. Tsuruo, and S. Gupta. Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 12:1457-1462 (1996).
32. J. A. Bilello, P. A. Bilello, K. Stellrecht, J. Leonard, D. W. Norbeck, D. J. Kempf, T. Robins, and G. L. Drusano. Human serum α-1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 40:1491-1497 (1996).